safety

Okubo Y, Morita A, Tada Y, Imafuku S, Armstrong AW, Blauvelt A, Vaile J, Popmihajlov Z, Li J, Sawant R, Habiro K, Tsuritani K, Ohtsuki[...]

Rugo HS, Jhaveri K, Pernas S, Pistilli B, Im SA, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu[...]

Berthelsen DB, Horgan B, Simon L, Ioannidis JPA, Goel N, Tugwell P, Balay-Dustrude E, Bartlett SJ, Bingham CO, Boers M, Bouillot C, Böhm P, Choy[...]

Berdahl CT, Schiff GD, Venkatesh AK, Seferian EG, Torbati SS, Ptacek MP, Carrascoza-Bolanos J, Qureshi N, Nuckols TK; Multidisciplinary ED Diagnostic Excellence Panel. Defining Diagnostic[...]

Esquenazi A, Wein TH, Verduzco-Gutierrez M, Ayyoub Z, Page S, Harding S, Maisonobe P, Beneteau M, Patel A; DIRECTION study group. A Phase IV, Randomized,[...]

Berthelsen DB, Haugegaard T, Kamso MM, Tugwell P, Simon LS, Ioannidis JPA, Flurey C, Boers M, Voshaar M, Richards P, Shea B, Furst DE, Singh[...]

Roney AR, Orr D, Barghi A, Hussani S, Cusumano V, Limketkai BN, Sauk JS. Longitudinal Safety Outcomes of Anti-tumor Necrosis Factor Alpha Therapy in the[...]

Rugo HS, Tolaney SM, Cortés J, Marmé F, de Azambuja E, Xu B, Sohn J, Naito Y, Valdez T, Gary D, Zhu J, Lai C,[...]

Khalid A, Balach R, Rasool A, Daniyal SM, Nizami MT, Gul I, Naqvi A, Fonarow GC, Waqas SA. Clinical outcomes and safety of SGLT2 inhibitors[...]

Hsue PY, Behrens GMN, Xu ZJ, Zhao Y, Cmar J, Lahoulou R, Campo RE, Plank RM. Cardiovascular Risk Assessment Using the Atherosclerotic Cardiovascular Disease (ASCVD)[...]